Other: 1) Screening inhibitors of PCSK9-LDLR interaction in vitro. 2) Characterization of inhibitor candidates of PCSK9-LDLR interaction in vitro. 3) Screening monoclonal antibody that inhibits PCSK9-LDLR interaction in vitro. 4) Characterization of PCSK
* VAT and and shipping costs not included. Errors and price changes excepted